Novartis bags Adakveo FDA approval to reduce VOCs in sickle cell disease

TAGS

Adakveo FDA approval : Swiss drugmaker Novartis has bagged approval for Adakveo (crizanlizumab-tmca) from the (FDA) for its use in .

Formerly known as SEG101, Adakveo has been indicated to be used for bringing down the frequency of vaso-occlusive crises (VOCs), or pain crises, in patients, aged 16 years and older with the genetic blood disorder.

According to the FDA, is a usual and painful complication of sickle cell disease caused by blocking of blood circulation by sickled red blood cells. Sickle cell disease is a genetic blood condition in which the red blood cells are shaped abnormally like a sickle. As a result, the sickle-shaped blood cells curb the flow in blood vessels and limit oxygen delivery to the body’s tissues, resulting in severe pain and organ damage.

See also  Pfizer gets FDA approval for tick-borne encephalitis vaccine TICOVAC

Adakveo is now the first FDA-approved sickle cell disease drug that binds to P-selectin, a cell adhesion protein that is considered to have a key role in the multicellular interactions that can result in vaso-occlusion.

Novartis Adakveo FDA approval to reduce VOCs in sickle cell disease

Novartis bags Adakveo FDA approval to reduce VOCs in sickle cell disease Photo courtesy of Novartis AG.

Brett P. Giroir – Acting FDA Commissioner, commenting on Adakveo FDA approval, said: “Hope has never been higher for people living with sickle cell disease and their families and supporters, with a pipeline of new treatments on the horizon, like the one being approved today, and several initiatives underway to better utilize current tools in the battle against the painful and deadly blood disorder.

See also  Mirum gets FDA breakthrough therapy status for maralixibat for Alagille syndrome

“The opportunity before us in the coming months and years is profound and historic.”

Basis of Adakveo FDA approval

Adakveo FDA approval was driven based on the findings of the SUSTAIN clinical trial featuring 198 sickle cell disease patients with a history of vaso-occlusive crisis. The randomized, placebo-controlled trial showed that the Novartis drug delivered a significant reduction in the median annual rate of VOCs to 1.63 vs 2.98 compared to placebo, which represents a reduction in frequency by 45%.

Novartis said that the reductions in the frequency of VOCs were noted among patients irrespective of sickle cell disease genotype and/or hydroxyurea use.

Commenting on Adakveo FDA approval, – Novartis Oncology President, said: “The approval of Adakveo marks a new era in the treatment of sickle cell disease, a genetic condition that places an extraordinary burden of unpredictable pain crises on patients and their families.

See also  AstraZeneca reports positive results for phase 2 COAST trial of oleclumab and monalizumab

“The stories we have heard from patients about their sickle cell pain crises are devastating. We are pleased to help reimagine medicine together with the sickle cell community and offer new hope for fewer VOCs.”

Recently, Novartis’ generic drug business Sandoz signed a deal to acquire the Japanese business of Aspen Global Incorporated (AGI) in a deal valued up to €400 million.

For more pharma regulatory news like Adakveo FDA approval and other pharma industry news, keep following Pharma News Daily.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This